Angiotensin Peptides and SARS-CoV-2: Mechanistic Insights into Enhanced Spike Protein Binding

Study Background and Research Question

The renin–angiotensin system (RAS) is a central regulator of cardiovascular and renal homeostasis, with angiotensin peptides orchestrating a broad spectrum of physiological effects. The emergence of SARS-CoV-2, the etiological agent of COVID-19, has drawn intense research attention to the RAS, given the virus’s reliance on angiotensin-converting enzyme 2 (ACE2) as a primary cell entry receptor. However, ACE2 is not the only portal exploited by the viral spike protein: alternative receptors such as neuropilin-1 (NRP1) and AXL also contribute to viral infectivity, particularly in cells with low ACE2 expression. Against this backdrop, the study by Oliveira et al. (DOI:10.3390/ijms26136067) investigates whether endogenous angiotensin peptides modulate the interaction between the SARS-CoV-2 spike protein and its cellular receptors, with a focus on AXL.

Key Innovation from the Reference Study

The central innovation of Oliveira et al. lies in the discovery that specific angiotensin peptides—including Angiotensin (1-7) (Asp-Arg-Val-Tyr-Ile-His-Pro)—can enhance the binding affinity of the SARS-CoV-2 spike protein to the AXL receptor. Previous models of COVID-19 pathogenesis emphasized the role of ACE2, but this work expands the mechanistic landscape by implicating RAS-derived peptides in the facilitation of viral entry via non-ACE2 receptors. Notably, both C-terminal and N-terminal truncations of angiotensin II yielded peptides with enhanced or altered capacity to promote spike–AXL interactions. This finding suggests a nuanced structure–function relationship and provides mechanistic rationale for exploring the RAS as a modulator of COVID-19 susceptibility and severity.

Methods and Experimental Design Insights

To dissect these interactions, the authors employed antibody-based binding assays quantifying the interaction between the SARS-CoV-2 spike protein and three host receptors: ACE2, NRP1, and AXL. A systematic panel of angiotensin peptides was synthesized, including full-length angiotensin I (1–10), angiotensin II (1–8), Angiotensin (1-7), and various N- and C-terminally truncated or chemically modified analogs. Peptide-induced modulation of spike–receptor binding was assessed by measuring changes in signal intensity relative to controls. In particular, substitutions at position 4 (tyrosine to valine, and tyrosine phosphorylation) were evaluated to probe the impact of specific amino acid modifications on peptide bioactivity.

Core Findings and Why They Matter

The study revealed several notable findings:

• Angiotensin II (1–8) nearly doubled spike–AXL binding, with no significant effect on ACE2 or NRP1 interactions.
• C-terminal truncation to Angiotensin (1-7) or Angiotensin (1-6) preserved the enhancement of spike–AXL binding, indicating that the heptapeptide Asp-Arg-Val-Tyr-Ile-His-Pro retains functional activity.
• N-terminal truncations (e.g., Angiotensin III [2–8], Angiotensin IV [3–8], and Angiotensin [2–7]) produced even more potent enhancement of spike–AXL binding, with Angiotensin IV inducing a 2.7-fold increase.
• Amino acid modifications at position 4, such as tyrosine-to-valine substitution or tyrosine phosphorylation, further boosted spike–AXL binding, implying a critical role for this residue in peptide–receptor modulation.
• Angiotensin IV also increased spike binding to ACE2 and NRP1, suggesting broader implications for viral attachment pathways.

These results underscore that endogenous heptapeptide hormones such as Angiotensin (1-7) can function as modulators of viral–host receptor interactions, extending their physiological significance beyond classical cardiovascular and renal contexts. This mechanism may help explain variable COVID-19 susceptibility in individuals with altered RAS activity.

Comparison with Existing Internal Articles

Previous internal analyses (Angiotensin (1-7): Mechanistic Frontiers and Strategic Opportunities) have emphasized Angiotensin (1-7)'s role as a Mas receptor agonist and its downstream effects on PI3K/AKT and ERK pathway modulation, anti-fibrotic, and anti-inflammatory responses. While these reviews focus on its established benefits in tissue protection and metabolic regulation, the current study uniquely positions Angiotensin (1-7) in a virology context, linking its molecular structure to enhanced spike–AXL binding. The cross-domain implication—bridging cardiovascular peptide biology with viral pathogenesis—was previously hypothesized but lacked direct experimental evidence until now.

Furthermore, workflow resources such as Optimizing Bench Protocols for Translational Research have provided guidance on leveraging Angiotensin (1-7) for anti-fibrotic and PI3K/AKT signaling studies. The findings from Oliveira et al. suggest an additional dimension for protocol design in virology and host–virus interaction assays where peptide-receptor modulation may be relevant.

Limitations and Transferability

While the data present a compelling mechanistic link between angiotensin peptides and spike protein–receptor binding, several limitations warrant discussion:

• The study used in vitro antibody-based binding assays, which, while specific, may not fully recapitulate the complexities of live cell viral entry or in vivo infection dynamics.
• Peptide concentrations and receptor expression levels in the experimental system may differ from physiological or pathological states in humans.
• The impact of endogenous peptide fluctuations, co-existing RAS modulators, and differential receptor distribution across tissues remains to be elucidated.
• There is no direct evidence yet linking peptide-mediated enhancement of spike–AXL binding with increased viral infectivity or disease severity in animal models or patients.

Therefore, while the findings are robust within the experimental framework, their translational relevance to clinical COVID-19 remains a subject for further investigation.

Why this cross-domain matters, maturity, and limitations

This cross-domain bridge—connecting RAS peptide research with viral pathogenesis—not only broadens mechanistic understanding but also raises important questions for therapeutic targeting. The maturity of this bridge is early-stage; while in vitro evidence demonstrates that Angiotensin (1-7) and related peptides modulate spike–AXL interactions, the in vivo and clinical implications are not yet established. Researchers should interpret these findings as foundational, warranting further validation in cellular and animal models before inferring clinical significance.

Protocol Parameters

• Peptide selection: Use high-purity Angiotensin (1-7) (Asp-Arg-Val-Tyr-Ile-His-Pro) to model RAS-derived effects on receptor–ligand interactions.
• Concentration guidance: Refer to prior cell-based studies, which commonly use 100 nM for in vitro modulation of PI3K/AKT or ERK signaling in kidney epithelial cells (as reported in product information), adapting as needed for receptor binding assays.
• Assay design: Employ ELISA or antibody-based binding assays for quantifying spike–receptor interactions, ensuring peptide–receptor stoichiometry is controlled.
• Peptide handling: Dissolve Angiotensin (1-7) in water or DMSO to ensure complete solubility and maintain structural integrity; short-term storage at -20°C is recommended for working solutions.
• Controls: Include negative controls (no peptide, scrambled peptide) and positive controls (known enhancing peptides such as Angiotensin II) to benchmark binding effects.

Research Support Resources

Researchers interested in exploring the role of angiotensin peptides in spike–receptor binding or broader PI3K/AKT and ERK pathway modulation can access high-purity Angiotensin (1-7) (SKU A1041) through APExBIO. This resource offers validated solubility and purity parameters suitable for advanced binding and signaling assays. For further protocol optimization and mechanistic analysis, consult recent workflows and peer-reviewed summaries from internal resources, such as "Mechanistic Frontiers and Strategic Opportunities."